AUROVERTIN F


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BSRDUXPTQGXEQN-XNXIQKSNSA-N
Smiles	COC1=CC(=O)OC(=C1C)\C=C\C=C\C=C\C2OC3(C)C(OC(C)(C2O)C3O)[C@H](C)O
InChI	InChI=1S/C23H30O8/c1-13-15(29-18(25)12-17(13)28-5)10-8-6-7-9-11-16-19(26)22(3)21(27)23(4,30-16)20(31-22)14(2)24/h6-12,14,16,19-21,24,26-27H,1-5H3/b7-6+,10-8+,11-9+/t14-,16?,19?,20?,21?,22?,23?/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H30O8
Molecular Weight	434.48
AlogP	0.74
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	6.0
Polar Surface Area	114.68
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	31.0

Assay Description	Organism	Bioactivity
Nematodexic activity against eggs of Meloidogyne incognita (root-knot nematode) assessed as mean corrected egg hatching inhibition rate at 25 to 400 ug/ml at 28 degC measured after 7 to 13 days by normal binocular microscopic analysis	Meloidogyne incognita	5.0 %
Nematodexic activity against mixed juvenile and adult stages of Panagrellus redivivus assessed as disruption of internal structure, vacuole formation and residual empty somatocysts in the dead worm at 28 degC measured after 48 hr by normal binocular microscopic analysis	Panagrellus redivivus	None
Nematodexic activity against mixed juvenile and adult stages of Panagrellus redivivus assessed as mean corrected mortality rate at 28 degC measured after 48 hr by normal binocular microscopic analysis	Panagrellus redivivus	88.6 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2227891
PubChem	76329523

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).